Author: admin

DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Pulmonary Arterial Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Arterial Hypertension Market Forecast

Some of the key facts of the Pulmonary Arterial Hypertension Market Report: 

• The Pulmonary Arterial Hypertension market size was valued approximately USD 4,838 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The evolving pipeline for pulmonary arterial hypertension (PAH) includes various treatments such as Sotatercept (MK-7962) from Merck, ralinepag by United Therapeutics, RT234 (vardenafil inhalation powder) developed by Respira Therapeutics, seralutinib (GB002) from Gossamer Bio, YUTREPIA (an inhaled dry powder formulation of treprostinil) created by Liquidia Technologies, and TNX-201 by Tenax Therapeutics. These treatments are anticipated to be introduced and made available throughout the forecast period from 2023 to 2032.
• In 2022, the collective number of existing cases of pulmonary arterial hypertension (PAH) in the 7MM (Seven Major Markets) was estimated to be around 88,100 cases. Over the study duration (2019─2032), it is anticipated that these cases will show a gradual increase, projected to grow at a Compound Annual Growth Rate (CAGR) of 0.4% by 2032
• In the European Union Four (EU4) and the United Kingdom (UK) combined, there were an estimated 19,720 diagnosed cases of pulmonary arterial hypertension (PAH) in 2022. It is anticipated that these diagnosed cases will experience an increase throughout the study period from 2019 to 2032.
• In 2022, Japan recorded an estimated 204 cases of class I, 1,143 occurrences of class II, 901 cases of class III, and 136 cases of class IV pulmonary arterial hypertension (PAH). It is anticipated that these figures will show a decline over the study period from 2019 to 2032.
• Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others   
• Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others
• The Pulmonary Arterial Hypertension epidemiology based on gender analyzed that females are more affected with Pulmonary Arterial Hypertension than males
• The Pulmonary Arterial Hypertension market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Arterial Hypertension pipeline products will significantly revolutionize the Pulmonary Arterial Hypertension market dynamics.

Pulmonary Arterial Hypertension Overview

When measured by right heart catheterization, pulmonary hypertension (PH) is defined as mean pulmonary artery pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during activity. PH has been classified into five groups by the World Health Organization (WHO) on the basis of shared pathophysiology, clinical presentation, and available treatments.

Get a Free sample for the Pulmonary Arterial Hypertension Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market

Pulmonary Arterial Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pulmonary Arterial Hypertension Epidemiology Segmentation:

The Pulmonary Arterial Hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Pulmonary Arterial Hypertension
• Prevalent Cases of Pulmonary Arterial Hypertension by severity
• Gender-specific Prevalence of Pulmonary Arterial Hypertension
• Diagnosed Cases of Episodic and Chronic Pulmonary Arterial Hypertension

Download the report to understand which factors are driving Pulmonary Arterial Hypertension epidemiology trends @ Pulmonary Arterial Hypertension Epidemiology Forecast

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched during the study period. The analysis covers Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pulmonary Arterial Hypertension Therapies and Key Companies

• AV-101: Aerovate Therapeutics
• LTP001: Novartis
• KER-012: Keros Therapeutics
• TPN171H: Vigonvita Life Sciences
• Treprostinil Palmitil: Insmed Incorporated
• Satralizumab (Genetical Recombination): Chugai Pharmaceutical
• Sotatercept: Merck Sharp & Dohme
• Macitentan: Janssen Pharmaceutical
• ACT-293987: Actelion
• GB002 (seralutinib): Gossamer Bio
• Parenteral Treprostinil: Lung Biotechnology PBC
• Ralinepag: United Therapeutics
• Selonsertib: Gilead Sciences
• Sotatercept: Acceleron Pharma
• ubenimex: Eiger BioPharmaceuticals
• Olaparib: AstraZeneca

Discover more about therapies set to grab major Pulmonary Arterial Hypertension market share @ Pulmonary Arterial Hypertension Treatment Landscape

Pulmonary Arterial Hypertension Market Strengths

• Better understanding of disease pathophysiology and genetics has improved diagnosis and treatment, reducing mortality
• There have been significant developments in the treatment regime leading to the approval of novel therapies and more defined treatment guidelines

Pulmonary Arterial Hypertension Market Opportunities

• Further research on diagnostic and prognostic blood biomarkers in asymptomatic or specific at-risk populations to improve diagnosis and develop novel treatment options
• The increasing prevalence of PAH, along with government support for the development of orphan drugs, provide companies with an excellent opportunity to invest in the PAH market

Scope of the Pulmonary Arterial Hypertension Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others
• Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others
• Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
• Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Pulmonary Arterial Hypertension Unmet Needs, KOL’s views, Analyst’s views, Pulmonary Arterial Hypertension Market Access and Reimbursement 

To know more about Pulmonary Arterial Hypertension companies working in the treatment market, visit @ Pulmonary Arterial Hypertension Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Pulmonary Arterial Hypertension Market Report Introduction

2. Executive Summary for Pulmonary Arterial Hypertension

3. SWOT analysis of Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension Patient Share (%) Overview at a Glance

5. Pulmonary Arterial Hypertension Market Overview at a Glance

6. Pulmonary Arterial Hypertension Disease Background and Overview

7. Pulmonary Arterial Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Pulmonary Arterial Hypertension 

9. Pulmonary Arterial Hypertension Current Treatment and Medical Practices

10. Pulmonary Arterial Hypertension Unmet Needs

11. Pulmonary Arterial Hypertension Emerging Therapies

12. Pulmonary Arterial Hypertension Market Outlook

13. Country-Wise Pulmonary Arterial Hypertension Market Analysis (2019–2032)

14. Pulmonary Arterial Hypertension Market Access and Reimbursement of Therapies

15. Pulmonary Arterial Hypertension Market Drivers

16. Pulmonary Arterial Hypertension Market Barriers

17.  Pulmonary Arterial Hypertension Appendix

18. Pulmonary Arterial Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pulmonary Arterial Hypertension Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Merck Sharp & Dohme, Janssen Pharma, Actelion, Gossamer Bio

The Tuberculosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Tuberculosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tuberculosis Market.

Some of the key takeaways from the Tuberculosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Tuberculosis treatment therapies with a considerable amount of success over the years. 
• Tuberculosis companies working in the treatment market are GlobeImmune, PDS Biotechnology, BioNTech, GlaxoSmithKline, Archivel Farma, GC Biopharma, Serum Institute of India Pvt. Ltd., Biofabri, S.L, Qurient Co, Shanghai Jiatan Pharmatech, Global Alliance for TB Drug Development, Theravectys, and others, are developing therapies for the Tuberculosis treatment 

• Emerging Tuberculosis therapies in the different phases of clinical trials are- GI-18000, PDS0201, BNT164, GSK2556286, GSK3036656, RUTI, GC3107A, VPM1002, MTBVAC, Telacebec, WX-081, TBAJ-876, Tuberculosis disease program, and others are expected to have a significant impact on the Tuberculosis market in the coming years.   
• In September 2022, Biofabri commenced a Phase III trial that is randomized, double-blind, and controlled. Its aim is to assess the effectiveness, safety, and immune response of MTBVAC in newborns who are both HIV unexposed and HIV exposed but uninfected, residing in Tuberculosis-Endemic areas within Sub-Saharan Africa.
• In March 2022, Bharat Biotech forged an alliance with Biofabri to collaboratively work on the development, production, and promotion of a novel Tuberculosis Vaccine. Bharat Biotech chose this vaccine candidate due to its progressed stage in clinical development and the encouraging outcomes observed in Phase I and Phase II clinical trials.
• In January 2022, The Phase II trial for pulmonary tuberculosis of GlaxoSmithKline’s GSK-3036656 led to a significant increase in its Phase Transition Success Rate (PTSR), rising by seven points to reach 55%.
• In March 2022, Bharat Biotech revealed a collaboration with Biofabri, a biopharmaceutical company from Spain, aimed at creating, producing, and introducing a new tuberculosis vaccine named ‘MTBVAC’. This partnership ensures the availability of TB vaccines across over 70 countries, with a particular focus on Southeast Asia and sub-Saharan Africa.
• In April 2022, Moderna and the non-profit scientific research group IAVI have joined forces in a fresh partnership to utilize mRNA technology. This collaboration aims to address various global health challenges, encompassing HIV/AIDS, tuberculosis (TB), antimicrobial-resistant enteric infections, and COVID-19.

Tuberculosis Overview

Lung disease is the most typical manifestation of tuberculosis (TB), an ancestor of human disease mostly caused by Mycobacterium tuberculosis. The respiratory system, gastrointestinal (GI) system, lymphoreticular system, skin, central nervous system, musculoskeletal system, reproductive system, and liver are the organ systems most frequently impacted.

Get a Free Sample PDF Report to know more about Tuberculosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/tuberculosis-pipeline-insight

Emerging Tuberculosis Drugs Under Different Phases of Clinical Development Include:

• GI-18000: GlobeImmune
• PDS0201: PDS Biotechnology
• BNT164: BioNTech
• GSK2556286: GlaxoSmithKline
• GSK3036656: GlaxoSmithKline
• RUTI: Archivel Farma
• GC3107A: GC Biopharma
• VPM1002: Serum Institute of India Pvt. Ltd.
• MTBVAC: Biofabri, S.L
• Telacebec: Qurient Co
• WX-081: Shanghai Jiatan Pharmatech
• TBAJ-876: Global Alliance for TB Drug Development
• Tuberculosis disease program: Theravectys

Tuberculosis Route of Administration

Tuberculosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Tuberculosis Molecule Type

Tuberculosis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Tuberculosis Pipeline Therapeutics Assessment

• Tuberculosis Assessment by Product Type
• Tuberculosis By Stage and Product Type
• Tuberculosis Assessment by Route of Administration
• Tuberculosis By Stage and Route of Administration
• Tuberculosis Assessment by Molecule Type
• Tuberculosis by Stage and Molecule Type

DelveInsight’s Tuberculosis Report covers around 35+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Tuberculosis product details are provided in the report. Download the Tuberculosis pipeline report to learn more about the emerging Tuberculosis therapies

Some of the key companies in the Tuberculosis Therapeutics Market include:

Key companies developing therapies for Tuberculosis are – GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Qurient Co., Sequella, Inc., Vaxil Biotherapeutics, Tianjin CanSino Biotechnology, Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, Global Alliance for TB Drug Development, BioNtech, TaBriX, Moderna, GC Biopharma, AJ Vaccines, Vaxxit Srl, Vaxil Bio Therapeutics, Vaxine Pty Ltd,  TVAX Biomedical, Theravectys SA, and others.

Tuberculosis Pipeline Analysis:

The Tuberculosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Tuberculosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tuberculosis Treatment.
• Tuberculosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Tuberculosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tuberculosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Tuberculosis drugs and therapies

Tuberculosis Pipeline Market Drivers

• Increasing R&D Investments and new drug developments, rising incidence of Tuberculosis are some of the important factors that are fueling the Tuberculosis Market.

Tuberculosis Pipeline Market Barriers

• However, high pricing of drugs specially second line treatment, lack of TB diagnostics and other factors are creating obstacles in the Tuberculosis Market growth.

Scope of Tuberculosis Pipeline Drug Insight    

• Coverage: Global
• Key Tuberculosis Companies: GlobeImmune, PDS Biotechnology, BioNTech, GlaxoSmithKline, Archivel Farma, GC Biopharma, Serum Institute of India Pvt. Ltd., Biofabri, S.L, Qurient Co, Shanghai Jiatan Pharmatech, Global Alliance for TB Drug Development, Theravectys, and others
• Key Tuberculosis Therapies: GI-18000, PDS0201, BNT164, GSK2556286, GSK3036656, RUTI, GC3107A, VPM1002, MTBVAC, Telacebec, WX-081, TBAJ-876, Tuberculosis disease program, and others
• Tuberculosis Therapeutic Assessment: Tuberculosis current marketed and Tuberculosis emerging therapies
• Tuberculosis Market Dynamics: Tuberculosis market drivers and Tuberculosis market barriers 

Request for Sample PDF Report for Tuberculosis Pipeline Assessment and clinical trials

Table of Contents

1. Tuberculosis Report Introduction

2. Tuberculosis Executive Summary

3. Tuberculosis Overview

4. Tuberculosis- Analytical Perspective In-depth Commercial Assessment

5. Tuberculosis Pipeline Therapeutics

6. Tuberculosis Late Stage Products (Phase II/III)

7. Tuberculosis Mid Stage Products (Phase II)

8. Tuberculosis Early Stage Products (Phase I)

9. Tuberculosis Preclinical Stage Products

10. Tuberculosis Therapeutics Assessment

11. Tuberculosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Tuberculosis Key Companies

14. Tuberculosis Key Products

15. Tuberculosis Unmet Needs

16 . Tuberculosis Market Drivers and Barriers

17. Tuberculosis Future Perspectives and Conclusion

18. Tuberculosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tuberculosis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | GlaxoSmithKline, Archivel Farma S.L, Qurient Co., Sequella, Inc., Vaxil

The Hyperalgesia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Hyperalgesia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hyperalgesia Market.

Some of the key takeaways from the Hyperalgesia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Hyperalgesia treatment therapies with a considerable amount of success over the years. 
• Hyperalgesia companies working in the treatment market are Domain Therapeutics, Oxford Cannabinoid Technologies Holdings plc, Initiator Pharma, VistaGen Therapeutics, and others, are developing therapies for the Hyperalgesia treatment 

• Emerging Hyperalgesia therapies in the different phases of clinical trials are- NPFFR antagonist, OCT461201, IP2015, AV-101, and others are expected to have a significant impact on the Hyperalgesia market in the coming years.   
• In September 2022, Initiator Pharma A/S, a clinical-stage pharmaceutical company, declared the acquisition of the conclusive dataset and completion of study report analysis for the IPTN2021 program. This program comprises a Phase I clinical study involving healthy subjects who were administered the drug IP2015 and exposed to a pain-inducing component (capsaicin).
• In January 2022, Initiator Pharma commenced a trial named ‘A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Utilizing the Intradermal Capsaicin Model.

Hyperalgesia Overview

Hyperalgesia is a condition characterized by an increased sensitivity to pain. It refers to an exaggerated response to painful stimuli, where a person experiences heightened pain sensations in response to stimuli that would not typically cause pain or would cause only mild discomfort.

Get a Free Sample PDF Report to know more about Hyperalgesia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hyperalgesia-pipeline-insight

Emerging Hyperalgesia Drugs Under Different Phases of Clinical Development Include:

• NPFFR antagonist: Domain Therapeutics
• OCT461201: Oxford Cannabinoid Technologies Holdings plc
• IP2015: Initiator Pharma
• AV-101: VistaGen Therapeutics

Hyperalgesia Route of Administration

Hyperalgesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Hyperalgesia Molecule Type

Hyperalgesia Products have been categorized under various Molecule types, such as

• Small molecule
• Oligonucleotide

Hyperalgesia Pipeline Therapeutics Assessment

• Hyperalgesia Assessment by Product Type
• Hyperalgesia By Stage and Product Type
• Hyperalgesia Assessment by Route of Administration
• Hyperalgesia By Stage and Route of Administration
• Hyperalgesia Assessment by Molecule Type
• Hyperalgesia by Stage and Molecule Type

DelveInsight’s Hyperalgesia Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hyperalgesia product details are provided in the report. Download the Hyperalgesia pipeline report to learn more about the emerging Hyperalgesia therapies

Some of the key companies in the Hyperalgesia Therapeutics Market include:

Key companies developing therapies for Hyperalgesia are – Novartis AG, Caventure Drug Discovery Inc, Charleston Laboratories Inc, Exodos Life Sciences Limited Partnership, and others.

Hyperalgesia Pipeline Analysis:

The Hyperalgesia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Hyperalgesia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hyperalgesia Treatment.
• Hyperalgesia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hyperalgesia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hyperalgesia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hyperalgesia drugs and therapies

Hyperalgesia Pipeline Market Drivers

• Promising Therapeutic Approaches, increasing Awareness of the Disease, recent Advancements in Research and Development are some of the important factors that are fueling the Hyperalgesia Market.

Hyperalgesia Pipeline Market Barriers

• However, obstacles in SLE Pipeline, hit and Trial Approach of Researchers, high Annual Cost of Therapies and other factors are creating obstacles in the Hyperalgesia Market growth.

Scope of Hyperalgesia Pipeline Drug Insight    

• Coverage: Global
• Key Hyperalgesia Companies: Domain Therapeutics, Oxford Cannabinoid Technologies Holdings plc, Initiator Pharma, VistaGen Therapeutics, and others
• Key Hyperalgesia Therapies: NPFFR antagonist, OCT461201, IP2015, AV-101, and others
• Hyperalgesia Therapeutic Assessment: Hyperalgesia current marketed and Hyperalgesia emerging therapies
• Hyperalgesia Market Dynamics: Hyperalgesia market drivers and Hyperalgesia market barriers 

Request for Sample PDF Report for Hyperalgesia Pipeline Assessment and clinical trials

Table of Contents

1. Hyperalgesia Report Introduction

2. Hyperalgesia Executive Summary

3. Hyperalgesia Overview

4. Hyperalgesia- Analytical Perspective In-depth Commercial Assessment

5. Hyperalgesia Pipeline Therapeutics

6. Hyperalgesia Late Stage Products (Phase II/III)

7. Hyperalgesia Mid Stage Products (Phase II)

8. Hyperalgesia Early Stage Products (Phase I)

9. Hyperalgesia Preclinical Stage Products

10. Hyperalgesia Therapeutics Assessment

11. Hyperalgesia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hyperalgesia Key Companies

14. Hyperalgesia Key Products

15. Hyperalgesia Unmet Needs

16 . Hyperalgesia Market Drivers and Barriers

17. Hyperalgesia Future Perspectives and Conclusion

18. Hyperalgesia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hyperalgesia Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis AG, Caventure Drug Discovery Inc, Charleston Laboratories

The Systemic Lupus Erythematosus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Systemic Lupus Erythematosus Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Lupus Erythematosus Market.

Some of the key takeaways from the Systemic Lupus Erythematosus Pipeline Report:

• Companies across the globe are diligently working toward developing novel Systemic Lupus Erythematosus treatment therapies with a considerable amount of success over the years. 
• Systemic Lupus Erythematosus companies working in the treatment market are Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others, are developing therapies for the Systemic Lupus Erythematosus treatment 

• Emerging Systemic Lupus Erythematosus therapies in the different phases of clinical trials are- Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others are expected to have a significant impact on the Systemic Lupus Erythematosus market in the coming years.   
• In February 2022, The National Medical Products Administration (NMPA) of China granted approval to GlaxoSmithKline’s Benlysta for the treatment of active lupus nephritis (LN) in adult patients within China.
• In February 2022, AstraZeneca’s Saphnelo (anifrolumab) received approval in the European Union as an additional therapy for the treatment of adult patients diagnosed with moderate to severe, active systemic lupus erythematosus (SLE) and who test positive for autoantibodies, despite already undergoing standard treatment.

Systemic Lupus Erythematosus Overview

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect various parts of the body. In this condition, the immune system mistakenly attacks healthy tissues and organs, leading to inflammation, pain, and damage to different systems within the body.

Get a Free Sample PDF Report to know more about Systemic Lupus Erythematosus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-pipeline-insight

Emerging Systemic Lupus Erythematosus Drugs Under Different Phases of Clinical Development Include:

• Mosunetuzumab: Roche
• Itolizumab: Equillium/ Biocon Limited
• KPG 818: Kangpu Biopharmaceuticals
• BOS161721: Boston Pharmaceuticals S
• NKTR-358: Nektar Therapeutics
• ABBV-599: AbbVie
• Daxdilimab (VIB7734): Horizon Therapeutics
• SAR441344: Sanofi
• BIIB059: Biogen
• Obinutuzumab: Hoffman-La-Roche

Systemic Lupus Erythematosus Route of Administration

Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Systemic Lupus Erythematosus Molecule Type

Systemic Lupus Erythematosus Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Systemic Lupus Erythematosus Pipeline Therapeutics Assessment

• Systemic Lupus Erythematosus Assessment by Product Type
• Systemic Lupus Erythematosus By Stage and Product Type
• Systemic Lupus Erythematosus Assessment by Route of Administration
• Systemic Lupus Erythematosus By Stage and Route of Administration
• Systemic Lupus Erythematosus Assessment by Molecule Type
• Systemic Lupus Erythematosus by Stage and Molecule Type

DelveInsight’s Systemic Lupus Erythematosus Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Systemic Lupus Erythematosus product details are provided in the report. Download the Systemic Lupus Erythematosus pipeline report to learn more about the emerging Systemic Lupus Erythematosus therapies

Some of the key companies in the Systemic Lupus Erythematosus Therapeutics Market include:

Key companies developing therapies for Systemic Lupus Erythematosus are – Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, F. Hoffmann-La Roche AG, Pfizer Limited, ImmuPharma PLC, Bristl Myers Squibb Company, AstraZeneca, Merck & Co., Inc., and others.

Systemic Lupus Erythematosus Pipeline Analysis:

The Systemic Lupus Erythematosus pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Lupus Erythematosus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Lupus Erythematosus Treatment.
• Systemic Lupus Erythematosus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Systemic Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Lupus Erythematosus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Systemic Lupus Erythematosus drugs and therapies

Systemic Lupus Erythematosus Pipeline Market Drivers

• Promising Therapeutic Approaches, increasing Awareness of the Disease, recent Advancements in Research and Development are some of the important factors that are fueling the Systemic Lupus Erythematosus Market.

Systemic Lupus Erythematosus Pipeline Market Barriers

• However, obstacles in Systemic Lupus Erythematosus Pipeline, hit and Trial Approach of Researchers, high Annual Cost of Therapies and other factors are creating obstacles in the Systemic Lupus Erythematosus Market growth.

Scope of Systemic Lupus Erythematosus Pipeline Drug Insight    

• Coverage: Global
• Key Systemic Lupus Erythematosus Companies: Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others
• Key Systemic Lupus Erythematosus Therapies: Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others
• Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies
• Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers 

Request for Sample PDF Report for Systemic Lupus Erythematosus Pipeline Assessment and clinical trials

Table of Contents

1. Systemic Lupus Erythematosus Report Introduction

2. Systemic Lupus Erythematosus Executive Summary

3. Systemic Lupus Erythematosus Overview

4. Systemic Lupus Erythematosus- Analytical Perspective In-depth Commercial Assessment

5. Systemic Lupus Erythematosus Pipeline Therapeutics

6. Systemic Lupus Erythematosus Late Stage Products (Phase II/III)

7. Systemic Lupus Erythematosus Mid Stage Products (Phase II)

8. Systemic Lupus Erythematosus Early Stage Products (Phase I)

9. Systemic Lupus Erythematosus Preclinical Stage Products

10. Systemic Lupus Erythematosus Therapeutics Assessment

11. Systemic Lupus Erythematosus Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Systemic Lupus Erythematosus Key Companies

14. Systemic Lupus Erythematosus Key Products

15. Systemic Lupus Erythematosus Unmet Needs

16 . Systemic Lupus Erythematosus Market Drivers and Barriers

17. Systemic Lupus Erythematosus Future Perspectives and Conclusion

18. Systemic Lupus Erythematosus Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Lupus Erythematosus Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Sanofi SA, Eli Lilly, Viatris, Novartis AG, GSK